Please use this identifier to cite or link to this item:
|Title:||SEOM clinical guidelines for diagnosis and treatment of glioblastoma (2017)|
|Author:||Martínez García, M.|
Álvarez Linera, J.
Martínez Aguillo, M.
Navarro, L. M.
Vaz Salgado, M. A.
Gil Gil, Miguel
Tractament adjuvant del càncer
Cancer adjuvant treatment
|Publisher:||Springer International Publishing Ag|
|Abstract:||Glioblastoma (GB) is the most common brain malignancy and accounts for over 50% of all high-grade gliomas. Radiotherapy (RT) with concomitant and adjuvant temozolomide (TMZ) chemotherapy is the current standard of care for patients with newly diagnosed GB up to age 70. Recently, a new standard of care has been adopted for elderly patients (65 years) based on short course of RT and TMZ. Several clinically relevant molecular markers that assist in diagnosis and prognosis have recently been identified. The treatment for recurrent GB is not well defined, and decision-making is usually based on prior strategies as well as several clinical and radiological factors. The presence of neurologic deficits and seizures can significantly impact quality of life.|
|Note:||Reproducció del document publicat a: https://doi.org/10.1007/s12094-017-1763-6|
|It is part of:||Clinical & Translational Oncology, 2018-01-01, Vol. 20, Issue 1, P. 22-28|
|Appears in Collections:||Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))|
This item is licensed under a Creative Commons License